Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2467${count})

  • Target Validation, 2010
    Gremlin-1, a Putative VTA-derived Neuroprotective Factor in Parkinson's Disease

    Objective/Rationale:
    We recently showed that certain brain neurons which are normally protected from Parkinson’s disease (PD) contain high levels of the developmental factor Gremlin-1. The goal of this...

  • Target Validation, 2010
    Treating Early Cognitive Impairments and Associated Movement Control Deficits by Stimulating alpha4beta2* nAChRs

    Objective/Rationale:
    Cholinergic systems decline early in PD and are hypothesized to contribute to cognitive impairments as well as to impairments in performing complex movements and postural...

  • Rapid Response Innovation Awards, 2010
    Down-regulation of GDNF Signaling in the Alpha-synuclein Model of PD: Implications for the Use of GDNF in Neuroprotective Therapy

    Objective/Rationale: 
    GDNF is currently the most effective, and best studied, survival factor acting on dopamine neurons (the neurons that die in Parkinson´s disease, PD). Infusion of GDNF into the...

  • Rapid Response Innovation Awards, 2010
    Identification of Small-molecule Stabilizers of DJ-1: Biophysical and Cellular Validation

    Objective/Rationale:
    The goal of our project is to develop an approach to treat PD by stabilizing wild-type dimeric DJ-1 with a small molecule. We hypothesize that this approach will lead to an...

  • Rapid Response Innovation Awards, 2010
    MicroRNAs as Biomarkers for Parkinson's Disease; A Comparison of CSF and Blood

    Objective/Rationale:
    We, and many other groups, hypothesize that miRNAs have the potential to be selective and sensitive diagnostic indicators for Parkinson’s disease. The focus of this project is to...

  • Target Validation, 2010
    Validation of FKBP Inhibitors to Target Alpha-synuclein Pathology in Pre-clinical Model Brain

    Objective/Rationale: 
    FK506 Binding Proteins (FKBPs) are enzymes that play a role in protein folding. FKBPs are highly expressed in human brain and are thought to be involved in neurodegenerative...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.